Abstract
Background: A pharmaceutical will be clinically accepted if it is impurity-free and its dose is accurately maintained. For this, the contribution of analytical techniques for developing and validating a new pharmaceutical dosage form cannot be overlooked.
Introduction: Tolterodine tartrate is a potent competitive muscarinic receptor antagonist. It binds to the muscarinic M3 receptors in the bladder selectively and competitively. It is used to treat urinary incontinence and overactive bladder syndrome. The 5-hydroxymethyl derivative is the pharmacologically active metabolite of Tolterodine tartrate, which is as potent as the main drug. It is available with α-adrenergic blocker Tamsulosin in combined pharmaceutical formulations, treating benign prostatic hyperplasia in men. This review article presents several analytical methods, including HPLC, HPTLC, UV-Visible spectrophotometry, spectrofluorimetry, electroanalytical, and various hyphenated techniques like GC-MS, LC-MS, LC-MS-MS, etc., for estimation of Tolterodine tartrate is present as a single material or in combined form in bulk materials, different pharmaceutical formulations, and biological matrices.
Conclusion: HPLC and spectrophotometry are the most widely used methods for determining the drug in the bulk and pharmaceutical dosage form among all these methods. LC-MS and LC-MSMS are widely used for the estimation of Tolterodine tartrate from plasma and other biological fluids. All the methods included in this article are accurate, sensitive, and cost-effective.
Keywords: Tolterodine tartrate, tamsulosin, analytical method, prostatic hyperplasia, spectrophotometry, muscarinic receptor, HPLC.
Graphical Abstract
[http://dx.doi.org/10.1002/(SICI)1099-081X(199903)20:2<91:AID-BDD162>3.0.CO;2-Y] [PMID: 10206324]
[http://dx.doi.org/10.1111/j.1365-2125.2011.03961.x] [PMID: 21392072]
[http://dx.doi.org/10.1517/17425255.2012.714365] [PMID: 22871042]
[http://dx.doi.org/10.1345/aph.18427] [PMID: 10534221]
[http://dx.doi.org/10.1186/1471-2490-14-84] [PMID: 25348235]
[http://dx.doi.org/10.1007/s11934-015-0531-9] [PMID: 26149965]
[http://dx.doi.org/10.1097/01.ju.0000176622.81796.89] [PMID: 16148673]
[http://dx.doi.org/10.3390/pharmaceutics8030027] [PMID: 27589789]
[http://dx.doi.org/10.1080/08998280.2007.11928310] [PMID: 17637888]
[http://dx.doi.org/10.1016/S0090-4295(99)00492-6] [PMID: 10767450]
[http://dx.doi.org/10.1177/00912700122010528] [PMID: 11402632]
[http://dx.doi.org/10.2165/00002018-200427130-00005] [PMID: 15471509]
[http://dx.doi.org/10.1067/mob.2001.116371] [PMID: 11483904]
[http://dx.doi.org/10.2217/17455057.2.2.251] [PMID: 19803897]
[http://dx.doi.org/10.1016/j.arabjc.2013.04.016]
[http://dx.doi.org/10.1001/jama.296.19.2319] [PMID: 17105794]
[http://dx.doi.org/10.4067/S0717-97072016000100005]
[http://dx.doi.org/10.3797/scipharm.1110-14] [PMID: 22396907]
[http://dx.doi.org/10.5958/2231-5675.2019.00015.2]
[http://dx.doi.org/10.1556/AChrom.23.2011.1.9]
[http://dx.doi.org/10.3797/scipharm.1407-18] [PMID: 26839802]
[http://dx.doi.org/10.1556/JPC.24.2011.2.13]
[http://dx.doi.org/10.1093/chromsci/bmx081] [PMID: 28977351]
[http://dx.doi.org/10.22159/ajpcr.2018.v11i2.21361]
[http://dx.doi.org/10.4103/0250-474X.32121]
[http://dx.doi.org/10.1186/1752-153X-6-105] [PMID: 22995678]
[http://dx.doi.org/10.1016/j.bfopcu.2012.07.006]
[http://dx.doi.org/10.4236/ajac.2012.311101]
[http://dx.doi.org/10.22159/ijpps.2018v10i4.24300]
[http://dx.doi.org/10.4314/tjpr.v13i10.14]
[http://dx.doi.org/10.22159/ajpcr.2017.v10i8.18794]
[http://dx.doi.org/10.14233/ajchem.2013.13210]
[http://dx.doi.org/10.2174/1573412913666170530124849]
[http://dx.doi.org/10.14235/bs.2016.500]
[http://dx.doi.org/10.1002/bio.3475] [PMID: 29578287]
[http://dx.doi.org/10.1016/j.jchromb.2009.02.036] [PMID: 19269904]
[http://dx.doi.org/10.1016/S0378-4347(99)00462-4] [PMID: 10677005]
[http://dx.doi.org/10.1016/S0731-7085(97)00023-X] [PMID: 9447563]
[http://dx.doi.org/10.1016/S0021-9673(98)00788-2] [PMID: 9916307]
[http://dx.doi.org/10.1016/j.jpha.2013.04.005] [PMID: 29403860]
[http://dx.doi.org/10.1365/s10337-010-1667-x]
[http://dx.doi.org/10.1016/j.talanta.2012.02.018] [PMID: 22817943]
[http://dx.doi.org/10.1002/elan.201200388]
[http://dx.doi.org/10.1134/S1061934814100049]